Quantcast

Industry news that matters to you.  Learn more

Archives for December 2012

New Technology May Enable Earlier Cancer Diagnosis

Finding ways to diagnose cancer earlier could greatly improve the chances of survival for many patients. One way to do this is to look for specific proteins secreted by cancer cells, which circulate in the bloodstream. However, the quantity of these biomarkers is so low that detecting them has proven difficult.

Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion’s Ovarian Cancer Test

Gynecologic Oncology, the prestigious medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1® which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer.

Tracking Down Smallest Biomarkers

Microvesicles are smallest cell elements which are present in all body fluids and are different, depending on whether a person is healthy or sick. This could contribute to detecting numerous diseases, such as, e.g., carcinomas, at an early stage, and to treating them more efficiently. The problem is that the diameter of the relevant microvesicles generally lies below 100 nm, which makes them technically detectable, but their exact size and concentration hardly possible to determine. A new device is now to provide the metrological basis for these promising biomarkers. The vacuum-compatible version of the Pilatus hybrid pixel detector for X-rays, which was developed by Dectris in cooperation with the Physikalisch-Technische Bundesanstalt (PTB), now allows also the size of nano-particles – which, to date, have been difficult to characterize – to be determined using small-angle X-ray scattering at low photon energies. The detector can also be used for other X-ray-based techniques.

How the Era of Personalized Medicine is Bearing Fruit

The Personalized Medicine World Conference, PMWC 2013, to be held on January 28-29, 2013 in Silicon Valley, is a two-day business and educational conference that provides real-world insights into personalized medicine and allows participants to join the discussion, interacting with key opinion leaders who are framing and forming the future of this rapidly changing industry. PMWC 2013 is co-hosted by Stanford Hospital & Clinics, SAP and Oracle.

Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform

Biocartis has launched its revolutionary detection platform, Dynamic Multi-Analyte Technology (“DMAT”), a proteomic and nucleic acid platform that provides ultra-high quality data analysis even at higher multiplex formats. The platform launched well ahead of plan and Biocartis has flipped from a late-stage development company into a commercial business.